

Special Issue

Recent Advancement for the Treatment of Hepatocellular Carcinoma

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is a major cause of death worldwide. Due to the eradication of hepatitis C virus by direct-acting antivirals and the suppression of hepatitis B virus replication by nucleoside analogs, the number of viral-related HCC cases is gradually decreasing. On the contrary, nonviral-related HCC in individuals with alcoholic liver disease and/or metabolic liver disease is increasing and is now an important public health concern. Recently, many new therapeutic modalities for the treatment of HCC, such as the next-generation microwave coagulation system, have been developed. In addition, multiple chemotherapy drugs have become available in recent years, and thus, the landscape of liver cancer treatment has changed dramatically. These developments have provided us with effective tools to combat HCC, but simultaneously, the way in which these modalities are used to treat HCC has become complex. In this special issue, experts on each topic will review recent advancements in their field and give us suggestions to manage the leading developments in the effective treatment of HCC.

Guest Editor

Dr. Kazuhiro Nouse

Department of Gastroenterology and Liver Disease Center, Okayama City Hospital, Okayama City, Japan

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/134258

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)